



August 13, 2015

Dear Manufacturers,

I am writing on behalf of Cabell Huntington Hospital, Inc. (CHHI) (340B ID #DSH510055) to inform manufacturers that CHHI recently underwent an audit by the Health Resources and Services Administration (HRSA) of CHHI's compliance with 340B Drug Pricing Program (340B Program) requirements.

As background, Cabell Huntington Hospital, Inc. qualified for the 340B Program as a disproportionate share hospital in Huntington, West Virginia and has participated in the 340B Program since April of 2005.

Through the audit process, Cabell Huntington Hospital, Inc. was found to have non-compliance within their 340B Program and responsible for repayment as a result of the following finding(s):

CHH dispensed 340B drugs to ineligible individuals, as prohibited by 42 USC 256b(a)(5)(B).

Cabell Huntington Hospital, Inc. has identified all affected manufacturers and has contacted each to notify them of these violations to begin a dialogue on a method for repayment to affected manufacturers.

If manufacturers have not received notification from CHHI and believe repayment may be owed for the violations described in this letter, or if you have any questions or comments regarding the violations described in this letter please contact Sherri Morgan, Director of Pharmacy Services at 304-526-2102 or 1340 Hal Greer Boulevard; Huntington, WV 25701.

Sincerely,

David Ward
Senior Vice President and Chief Financial Officer
Cabell Huntington Hospital, Inc.